secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001108205-24-000035
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis expands TakeAim Leukemia study to 30 patients; 6/11 FLT3m and 4/18 SFm respond
--------------------------------------------------------------------------------

- TakeAim Leukemia dataset expanded from 5 to 30 R/R AML patients (25 new) with emavusertib monotherapy at 300 mg BID.
- FLT3m cohort: 6/11 evaluable patients achieved objective response (3 CR, 1 CRh, 2 MLFS); responses mostly in one cycle.
- SFm cohort: 4/18 evaluable patients achieved objective response (1 CR, 2 CRh, 1 MLFS); 3 additional patients showed increased neutrophils.
- All responders had complete bone marrow blast normalization; two patients proceeded to allogenic stem cell transplant.
- Curis discloses insufficient cash to fund operations for next 12 months, highlighting need for additional capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000035/0001108205-24-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000035/cris-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001108205-24-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer